The new biotechnological medicines are currently known also as ‘Biosimilars. They may be named also ‘similar biological medicinal products’ or ‘Biogenerics’. Biosimilars are an important part of biopharmaceuticals, with comparable safety and efficacy to reference products, whilst less expensive and therefore much affordable. Oxbridge has a business goal in creating therapeutic Biosimilars based on its protein engineering technology. Oxbridge is dedicated continuously to develop niche protein products, such as immunotoxins and recombinant antibodies.


Oxbridge has a product of Botulinum Toxin Type A. This preparation is a lyophilized white powder for injection in a colorless transparent vial.

For further documentation see the Patient Information Leaflets